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 a  Arkin Mental Health Institute,  Amsterdam ,  b  Altrecht Psychosomatic Medicine,  Utrecht ,  c  Department of Psychiatry, 
University Medical Centre,  Groningen , and  d  Department of Clinical Psychology, Faculty of Psychology and Education, 
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chotherapy may be preferable in mildly and moderately de-
pressed outpatients. For patients who receive either PDT or 
antidepressants, combined therapy after early nonresponse 
seems to be helpful. Nevertheless, this sequential strategy is 
not always preferred by patients. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The different forms of psychotherapy and pharmaco-
therapy appear to be equally effective in the acute treat-
ment of moderate-to-severe depression  [1–4] . The combi-
nation of psychotherapy and pharmacotherapy seems to 
be more beneficial than pharmacotherapy alone  [5–8] , 
especially in severe depression. However, the advantage 
of combined treatment over monopsychotherapy is less 
clear-cut  [9–12] .
 It is not unusual in clinical practice to start with 
monotreatment: there are cost-efficacy considerations, 
not all treatment options are available, there are possible 
side effects and adherence is higher in monotherapies  [13, 
14] . A sequential strategy may be used in patients who fail 
to respond. Segal et al.  [13] and Fava et al.  [14, 15] recom-
mend sequencing pharmacotherapy and psychotherapy 
 Key Words 
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 Abstract 
 Background: Insufficient response to monotreatment for 
depression is a common phenomenon in clinical practice. 
Even so, evidence indicating how to proceed in such cases is 
sparse.  Methods: This study looks at the second phase of a 
sequential treatment algorithm, in which 103 outpatients 
with moderately severe depression were initially random-
ized to either short-term supportive psychodynamic therapy 
(PDT) or antidepressants. Patients who reported less than 
30% symptom improvement after 8 weeks were offered 
combined treatment. Outcome measures were the Hamilton 
Depression Rating Scale (HAM-D), the Clinical Global Impres-
sion of Severity and Improvement, the SCL-90 depression 
subscale and the EuroQOL questionnaire.  Results: Despite 
being nonresponsive, about 40% of patients preferred to 
continue with monotherapy. At treatment termination, pa-
tients initially randomized to PDT had improved more than 
those initially receiving antidepressants, as indicated by the 
HAM-D and the EuroQOL, independently of whether the ad-
dition was accepted or not.  Conclusions: Starting with psy-
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for depression, especially for more severely depressed pa-
tients  [13] , but sequential strategies of this kind have not 
often been studied. We are aware of only one study (look-
ing at women with recurrent depression  [16] ) in which 
pharmacotherapy was prescribed after unsuccessful psy-
chotherapy. This appeared to be slightly more effective 
than combined therapy from the start  [16] . The reverse 
sequence – the addition of psychotherapy after nonre-
sponse to pharmacotherapy for depression – has been 
studied more frequently  [17–27] . In all of these studies, 
the psychotherapy was a form of cognitive behavior ther-
apy and it was mainly added to prevent relapse after par-
tially or fully successful pharmacotherapy.
 The aim of the present study was to determine which 
sequence is preferable for the acute treatment of depres-
sion: starting with psychodynamic therapy (PDT) or 
with pharmacotherapy. Although PDT is effective in de-
pression  [28–35] , it has never been studied in a sequen-
tial treatment design. This study started with a random-
ized clinical trial of 8 weeks, making a direct compari-
son between antidepressants (AD) and short-term, 
supportive PDT. In a previous article  [36] , we reported 
slightly better results for AD by week 4. This benefit had 
almost disappeared by week 8. This article covers the 
entire course of treatment and focuses on the differential 
efficacy of the treatment strategies after 24 weeks. At 
8 weeks, all patients with less than a 30% decrease in 
symptoms were offered combined therapy for an addi-
tional period of 16 weeks. Nonresponsive patients re-
ceiving AD were therefore offered complementary PDT, 
while nonresponsive patients receiving PDT were of-
fered complementary AD.
 The aim of this article is to explore the acceptability, 
feasibility and efficacy of the sequential treatment strate-
gies in cases of poor response after 8 weeks of treatment. 
Secondly, we hoped to determine which of the sequential 
strategies would be preferable: complementary AD after 
PDT or complementary PDT after AD.
 Methods 
 Subjects 
 The study sample comprised all consecutive patients newly 
registered over a period of 3 years at two outpatient clinics of Men-
trum Mental Health Care, a large psychiatric academic hospital 
with extensive outpatient facilities in the city of Amsterdam. The 
inclusion criteria were: age between 18 and 65 years, DSM-IV-
defined Depressive Episode with or without dysthymia (using the 
CIDI), a 17-item Hamilton Depression Rating Scale (HAM-D) 
 [37] baseline score between 14 and 26 points, and written in-
formed consent. The exclusion criteria were: bipolar disorder, 
drug abuse, psychotic symptoms, serious communicative prob-
lem (language, for example) or physical restrictions (patient due 
to leave the country soon, for example) precluding participation, 
the necessity of immediate hospitalization or day treatment, and 
contraindication for ADs (inability to stop using present psycho-
tropic medication, or pregnancy).
 Study Design 
 Figure 1 shows a flow diagram for the study population. Dur-
ing the study period 480 patients met the inclusion criteria for 
depression as determined by the regular intake procedure of the 
departments and confirmed with the CIDI. We excluded 276 pa-
tients for the following reasons: HAM-D score  ! 12 (n = 44), 
HAM-D score  1 25 (n = 135), and refusal to participate (n = 43) or 
other reasons (n = 54). In addition, another 63 patients dropped 
out during intake and before the randomization procedure. The 
reasons here were organizational: the overly long absence of the 
patients due to, for example, a holiday. In conclusion, 71 patients 
were allocated to PDT and 72 to AD.
 After randomization, 8 patients (n = 1 in the PDT arm and 
n = 7 in the AD arm) refused the randomized intervention and 
decided to follow their own preferred course of treatment  [36, 38] . 
Fifteen patients (n = 3 in the PDT arm and n = 12 in the AD arm) 
refused all treatment and 15 patients (n = 8 in the PDT arm and 
n = 7 in the AD arm) did not show up.
Excluded (n = 276)
HAM-D score <12 (n = 44)
HAM-D score >25 (n = 135)
Refused participation (n = 43)



















 Fig. 1. Flow of participants through the first stages of the random-
ized trial. 
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 Finally, 103 patients were included in the per protocol analysis 
(these were the patients who actually started treatment): 59 to the 
psychotherapy group and 44 to the pharmacotherapy group.
 After 8 weeks of treatment, a sequential strategy was imple-
mented. Insufficient response was defined as  ! 30% HAM-D re-
duction. This cut-off was based on clinical consensus. On the one 
hand, it reflects slightly more improvement then the usual opera-
tionalization of  ! 25% decrease for complete nonresponse [39–
42]. On the other hand, it reflects a realistic approach to the ex-
pected change in the first phase of psychotherapy. These nonre-
sponsive patients were offered the complementary treatment: 
additional PDT or AD for the remainder of the research period, 
i.e. until week 24. All other patients continued monotreatment 
until week 24.
 Treatment 
 Pharmacotherapy. Pharmacotherapy was provided in ac-
cordance with an AD protocol. All patients started with the se-
rotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine 
(75 mg/day). Depending on clinical response and tolerability, the 
dose of venlafaxine could be titrated up to a maximum of 225 mg/
day. In cases of intolerance (according to both psychiatrist and 
patient), the first-choice AD could be replaced by citalopram 
(maximum dose 60 mg/day) or nortriptyline (maximum dose 
150 mg/day). Patients had four fortnightly appointments with the 
pharmacotherapist in the first 2 months and appointments once 
a month in the second phase of treatment. Except for the first 
visit, all appointments lasted a maximum of 20 min, during which 
adequate clinical management was provided. All pharmacothera-
pists, either psychiatrists or residents, were experienced in the 
pharmacological treatment of depression. Residents were super-
vised regularly by psychiatrists.
 Psychotherapy. The psychotherapy consisted of sixteen ses-
sions of short-term, supportive PDT. A range of trials and studies 
have demonstrated its effectiveness in the treatment of depression 
 [7, 9, 38, 42–52] . The first eight sessions took place weekly, the last 
eight fortnightly. PDT is a manual-based approach focusing on 
the affective, behavioral and cognitive aspects of relationships 
from a psychodynamic point of view  [53, 54] . Initially, these areas 
are discussed from an interpersonal perspective, in other words 
the actual relationship with others. Subsequently, the therapist 
proceeds to an intrapersonal perspective by focusing on the inter-
nalizations of former relationships that are relevant to the vulner-
ability to depression.
 Depending on the focus of therapy and patients’ capacities, 
the therapists may choose more supportive interventions – such 
as encouraging adaptive coping mechanisms, guilt-reducing 
thoughts or giving praise – or interventions for enhancing insight 
such as exploring affects or confrontation. Manifestations of de-
fense mechanisms and transference are recognized and discussed 
if appropriate but not interpreted in depth. This means that the 
therapy is psychodynamic in terms of the intended therapeutic 
process and supportive in terms of the therapist’s basic attitude. 
It differs from IPT by using psychodynamic concepts and because 
of the focus on the interdependence of actual relationships and 
intrapersonal representations.
 PDT is used regularly by the participating outpatient depart-
ments to treat depressed patients. Therapists were trained in the 
principles of PDT (using the SPSP manual  [53, 54] ) in a 15-hour 
course, and were required to have completed one or more super-
vised therapies (depending on previous psychotherapeutic expe-
rience) before providing treatment in the research setting. Thera-
pist competence in PDT was evaluated by one of the supervisors 
before the therapists were allowed to participate in the current 
study. The two study supervisors were psychoanalytic psycho-
therapists registered with the Dutch Association of Psychoana-
lytic Psychotherapy. Thirteen therapists (8 female and 5 male) 
participated in this trial. They were either psychiatrists (n = 4), 
advanced residents in psychiatry (n = 3), psychotherapists (n = 3) 
or advanced psychotherapy trainees (n = 3). During the research 
project, there was weekly supervision for the residents and train-
ees. The other therapists met twice a week for peer supervision, 
together with one of the study supervisors. Supervision of integ-
rity was based on audio-taped material of sessions and focused on 
the course of depressive symptoms, the optimization of the thera-
peutic process, and the technical quality of interventions. The su-
pervisors also monitored adherence to the psychotherapy manu-
al, although this was not formally assessed. 
 Primary and Secondary Outcome Measures 
 The primary instrument was the 17-item HAM-D  [37] . HAM-
D data were provided by independent observers (three research 
fellows who were blind to the treatment condition). Data were 
gathered using a semistructured interview  [55, 56] . The reliability 
of observer assessments was assessed prior to participation in the 
study. During the study, the research assistants discussed their 
audiotaped assessments monthly with an experienced psychia-
trist.
 There were several secondary outcome measures. The Clinical 
Global Impression of severity and improvement (CGI-S, CGI-I 
 [57] ) was used. CGI data were provided by the treating clinicians. 
In addition, the depression subscale of the Ninety Symptom 
Checklist (SCL-D)  [58] was used as a self-report measure. Finally, 
the EuroQOL questionnaire, an instrument developed for evalu-
ating health and health care  [59] , was used to measure health sta-
tus. For pragmatic reasons, only item 5 was used. This is a self-
rated 10-point visual analogue scale asking the patient: ‘How 
good or bad is your general health status today?’ In short, our ef-
ficacy assessments were based on data from three sources: the 
treating clinicians, the patients and independent observers.
 The second phase of the trial included assessments at week 8, 
week 16 and week 24. Efficacy was expressed as differences in 
mean scores. HAM-D response was defined as a 50% symptom 
reduction. The criterion for complementary treatment was a re-
duction of less than 30% on the HAM-D and it was used at week 
8 only.
 Psychotherapy patients who completed fewer than five therapy 
sessions in the first 8 weeks or who terminated participation be-
tween weeks 8 and 24 were considered to be dropouts, whatever 
the reasons. AD drop-out was defined as self-reported noncom-
pliance with the medication regime or no-shows at follow-up ap-
pointments with the pharmacotherapist prior to week 16.
 Statistical Analysis 
 Pearson   2 calculations were used to compare baseline char-
acteristics, refusal rates, drop-out rates and success rates between 
therapy conditions. ANOVA was used to compare the baseline 
measurements of the two groups.
 ANCOVA analyses were used to test between-group differ-
ences in terms of means, including baseline measures, and pos-
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sible differences in baseline characteristics between therapy con-
ditions as covariates.
 Data analyses were performed on a per protocol sample and 
on an observed cases sample. The per protocol sample included 
all the patients who started treatment. last observation carried 
forward (LOCF) was applied to the per protocol sample for miss-
ing data. The observed cases sample included only the observed 
data for all patients who completed treatment.
 A general linear model repeated-measures analysis (GLM pro-
cedure in SPSS) was conducted to test the efficacy of the two se-
quential strategies. Time, initial strategy (PDT or AD), comple-
mentary therapy (in case of nonresponse), and the interaction be-
tween treatment group and complementary therapy were entered 
as predictors of the mean HAM-D score at week 24. Possible dif-
ferences between baseline characteristics in the therapy condi-
tions were also entered.
 The power of the trial was about 0.7 for 103 patients to deter-




 Table 1 shows the demographic and clinical character-
istics for the per protocol patient sample. No differences 
were found between the therapy groups, except for the use 
of medication in the three months preceding admission. 
In the pharmacotherapy group, significantly (  2 = 4.41; 
d.f. = 1; p = 0.04) more patients had been using medication 
prior to intake at our outpatient clinic (51.2 vs. 30.4%).
 Phase 1 (Weeks 0–8) 
 By week 8, sixteen (36.4%) of the randomized pharma-
cotherapy patients (n = 44) achieved a reduction of more 
than 30%. Eleven of the 59 randomized patients in the psy-
chotherapy group (18.6%) achieved a reduction of more 
than 30%. This difference was significant (  2 = 4.09; d.f. = 
1; p = 0.043). In the analyses of the mean severity scores 
we found that, by week 8, the AD group was significantly 
better off than the PDT group on the HAM-D and the 
SCL-D depression subscale (both in the per protocol and 
observed cases samples) ( table 2 ). The other assessments 
for more general clinical functioning, i.e. CGI and Euro-
QOL, did not show any significant improvement.
 The patients with a reduction of more than 30% con-
tinued with the same monotreatment. All nonresponsive 
patients were offered the option of moving on to the com-
bination therapy. Not all nonresponders accepted the ad-
ditional therapy. Of the 29 nonresponsive patients in the 
PDT condition, 17 (58.6%) started with the additional 
therapy. Twelve of the 18 patients (66.7%) in the AD con-
dition did so. The remaining patients continued mono-
treatment as scheduled. The percentages for the accep-
tance of additional therapy proved (with   2 testing) to be 
about the same in both groups.
 Attrition Rates 
 By 8 weeks, no significant differences in attrition rates 
were found (32.2% (n = 19) in the allotted psychotherapy 
Table 1. P atient characteristics (per protocol sample)
Psycho-
therapy
(n = 59, %)
Pharmaco-
therapy
(n = 44, %)
Total
(n = 103, %)
Sex
Male 25.4 27.3 26.2
Female 74.6 72.7 73.8
Age
20–29 years 32.2 15.9 25.2
30–39 years 35.6 43.2 38.8
40–49 years 16.9 27.3 21.4
50–60 years 15.3 13.6 14.6
Education level
Low 24.1 38.1 30.2
Intermediate 50.0 42.9 46.9
High 25.9 19.0 22.9
Patient was on medication 3 months prior to admission1
Yes 30.4 51.2 39.4
No 69.6 48.8 60.6
Psychiatric treatment for present episode
Treated 43.6 43.2 43.5
Not treated 56.4 56.8 56.5
Duration of present episode
<1 year 48.2 44.1 46.7
1–2 years 23.2 17.6 21.1
>2 years 28.6 38.2 32.2
Depressive episodes in past 5 years
0 48.2 47.6 48.0
1 41.1 42.9 41.8
2 5.4 2.4 4.1
≥3 5.4 7.1 6.1
HAM-D score
Mean 20.4 19.8 20.1
SD 3.8 3.7 3.7
Median 20.0 20.0 20.0
CGI-S score
Mean 4.4 4.1 4.3
SD 0.7 0.7 0.7
Median 4.0 4.0 4.0
SCL-D score
Mean 51.8 51.5 51.7
SD 10.0 11.6 10.6
Median 51.5 53.0 52.5
1 2 = 4.41; p = 0.036.
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Table 2.  Mean scores for the four outcome measures in the two study samples, with between-group test results, controlling for baseline 
differences (ANCOVA)
Psychotherapy Pharmacotherapy T otal F p
mean SD n mean SD n mean SD n 
Per protocol sample
HAM-D
Week 0 20.39 3.78 59 19.82 3.68 44 20.15 3.73 103 0.376 0.541
Week 8 18.39 6.51 59 15.59 6.45 44 17.19 6.60 103 4.398 0.039
Week 16 15.83 7.41 59 16.02 6.93 44 15.91 7.17 103 0.066 0.797
Week 24 13.34 8.08 59 16.07 7.58 44 14.50 7.95 103 3.572 0.062
CGI-S
Week 0 4.42 0.74 55 4.14 0.74 43 4.30 0.75 98 2.667 0.106
Week 8 3.60 1.07 57 3.32 0.91 44 3.48 1.01 101 1.822 0.180
Week 16 3.05 1.25 57 3.07 1.00 44 3.06 1.14 101 0.154 0.696
Week 24 2.65 1.34 57 3.00 1.33 44 2.80 1.34 101 2.663 0.106
CGI-I
Week 0
Week 8 3.25 0.91 57 3.05 0.94 42 3.16 0.92 99 1.576 0.212
Week 16 2.91 1.15 57 2.69 0.84 42 2.82 1.03 99 1.928 0.168
Week 24 2.63 1.17 57 2.71 1.15 42 2.67 1.16 99 0.172 0.680
SCL-D
Week 0 51.80 9.96 56 51.53 11.59 38 51.69 10.59 94 0.002 0.961
Week 8 46.64 12.92 58 41.88 12.62 42 44.64 12.95 100 11.410 0.001
Week 16 41.22 14.25 58 39.84 13.28 43 40.63 13.79 101 1.110 0.295
Week 24 37.24 14.74 58 39.60 13.70 43 38.25 14.29 101 0.288 0.593
EuroQOL
Week 0 5.18 1.42 45 4.87 1.55 30 5.05 1.47 75 0.518 0.474
Week 8 5.44 1.50 55 5.70 1.74 40 5.55 1.60 95 0.434 0.512
Week 16 5.95 1.65 55 5.59 1.82 41 5.79 1.72 96 0.606 0.439
Week 24 6.36 1.66 55 5.33 2.17 42 5.92 1.96 97 8.469 0.005
Observed cases sample
HAM-D
Week 0 20.33 3.87 59 19.82 3.73 44 20.15 3.73 103 0.376 0.541
Week 8 18.04 6.98 48 14.56 6.07 39 16.48 6.78 87 4.450 0.038
Week 16 12.89 7.16 37 14.97 7.06 30 13.82 7.14 67 1.544 0.219
Week 24 9.84 6.81 37 15.45 8.05 31 12.40 7.86 68 11.498 0.001
CGI-S
Week 0 4.42 0.74 55 4.14 0.74 43 4.30 0.75 98 2.667 0.106
Week 8 3.55 1.04 42 3.08 0.84 26 3.37 0.99 68 2.354 0.130
Week 16 2.69 1.17 36 2.74 0.99 19 2.71 1.10 55 0.052 0.821
Week 24 2.19 1.11 31 2.95 1.54 19 2.48 1.33 50 4.330 0.043
CGI-I
Week 0
Week 8 3.24 0.91 42 3.00 1.06 26 3.15 0.97 68 0.664 0.418
Week 16 2.75 1.25 36 2.42 0.77 19 2.64 1.11 55 1.707 0.197
Week 24 2.20 1.06 30 2.63 1.30 19 2.37 1.17 49 1.647 0.206
SCL-D
Week 0 51.80 9.96 56 51.53 11.59 38 51.69 10.59 94 0.002 0.961
Week 8 43.28 12.37 39 39.66 11.96 32 41.65 12.23 71 6.629 0.012
Week 16 35.55 14.24 31 37.79 11.50 28 36.61 12.95 59 0.310 0.580
Week 24 31.27 12.14 30 38.12 13.47 26 34.45 13.11 56 3.648 0.062
EuroQOL
Week 0 5.18 1.42 45 4.87 1.55 30 5.05 1.47 75 0.518 0.474
Week 8 5.58 1.58 40 5.79 1.87 28 5.66 1.70 68 0.010 0.922
Week 16 6.45 1.67 31 5.48 1.72 27 6.00 1.75 58 4.832 0.034
Week 24 6.80 1.57 35 5.39 2.41 23 6.24 2.05 58 13.491 0.001
Italics = p < 0.1; bold = p < 0.05.
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condition and 22.7% (n = 10) in the allotted pharmaco-
therapy condition). Between weeks 8 and 24, one patient 
in the PDT group dropped out of therapy at week 12 and 
4 dropped out at week 16 (5 patients in total). In the AD 
group, 4 patients terminated their treatment at week 12 
and 2 patients did so at week 16 (6 patients in total). These 
percentages (12% in PDT and 18% in AD) were not sig-
nificantly different. It can therefore be seen that drop-out 
mainly occurred in the first phase. Over the total re-
search period, 40 out of 103 patients (38.7%) dropped out 
from the treatment groups taken together.
 Overall Efficacy of the Sequential Treatment 
Algorithms 
 Table 2 presents the efficacy results during the total 
treatment period expressed as mean scores in the per pro-
tocol sample and the observed cases sample (between-
group differences were tested using ANCOVA to check 
for baseline differences).
 By week 8, the AD group was better off than the PDT 
group. However, after week 8, the pattern of results was 
reversed. By week 16, the two groups had about the same 
scores in almost all respects, with the exception of qual-
ity of life: the PDT group had significantly higher quality 
of life scores. The patients who started with PDT in the 
per protocol sample had better results at the end of treat-
ment than those who started with AD (according to the 
SCL-D and the EuroQOL). Furthermore, a trend was 
found with respect to the HAM-D. In the observed cases 
sample, all but one of the four measures significantly fa-
vored patients who started with PDT. There was a trend 
with respect to the SCL-D.
 We used a GLM repeated measures analysis to test the 
influence of the independent variables – time, initial 
strategy, the additional treatment, and the interaction of 
initial strategy and the additional treatment – on the se-
verity of symptoms during the treatment period (the de-
pendent variables in the GLM analysis were the scores for 
HAM-D, CGI, SCL and EuroQOL at T0, T8, T16 and 
T24).  Table  3 sets out the statistical parameters (the 
Greenhouse-Geisser F and p) for the independent vari-
ables in the analysis.
 In the per protocol and observed cases samples, the 
sample time and initial strategy had a significant influence 
on the decline of severity. Symptom severity was reduced 
over the research period. At the end of treatment, the PDT-
first strategy had produced significantly better results (us-
ing almost all measures) than the AD-first strategy.
 Additional treatment after week 8 resulted in a greater 
reduction of the HAM-D scores than no additional treat-
ment in both samples. In the per protocol sample, addi-
tional treatment also produced better results as reported 
by the patients and as assessed by the therapists.
 The interaction of initial strategy and additional treat-
ment was only significant in the per protocol sample for 
the CGI measures. The power for testing time (as a fac-
tor), initial strategy and additional treatment factors var-
ied from 0.70 to 0.99. The power for testing the interac-
tion variable was too low in almost all cases (varying from 
0.06 to 0.5), except in the cases of the significant interac-
tions in the per protocol sample: power for testing CGI-S 
0.93, and 0.63 for testing CGI-I.
 To illustrate the slopes in the four groups, online
suppl. fig. 1 (www.karger.com/doi/10.1159/000341177) 
shows the mean scores on HAM-D for the four groups 
during the treatment (from the per protocol samples).
 Almost all the measures showed the same pattern. In 
the beginning, patients using AD improved more, but 
PDT led to better results in the end.
 Secondary Analyses 
 In the analyses above, we allocated all the patients to 
four subgroups: ADT or PDT patients with or without 
addition. Another approach to making subgroups in this 
complex study is to divide all the patients into three sub-
samples: responders (without addition), nonresponders 
with addition and nonresponders without addition. We 
used GLM to test the possible differences in outcome be-
tween the two initial strategies (AD or PDT) in these 
three subsamples. Because of the smaller sample sizes, we 
also state the observed power here.
 In the secondary GLM subgroup analyses (of the HAM-
D scores at T0, T8, T16 and T24) for responders only, the 
interaction effect was a trend (F = 2.46; p = 0.079; observed 
power = 0.54). The AD responders did not improve sig-
nificantly any further between weeks 8 and 24 (mean T0: 
19.21; mean T8: 9.95; mean T16: 13.11; mean T24: 12.95). 
This contrasted with the PDT responders (mean T0: 18.31; 
mean T8: 9.46; mean T16: 9.31; mean T24: 6.77).
 In similar secondary GLM subgroup analyses of the 
group of nonresponders who refused additional therapy, 
we also found an interaction effect that was a trend (F = 
2.37; p = 0.10; observed power = 0.46). The AD nonre-
sponders who refused additional PDT did not improve 
significantly between weeks 8 and 24 (mean T0: 21.00; 
mean T8: 20.92; mean T16: 20.58; mean T24: 21.75). This 
contrasted with the nonresponsive PDT patients who re-
fused additional AD. There was a trend of improvement 
between week 8 and week 24 (mean T0: 20.81; mean T8: 
20.46; mean T16: 19.35; mean T24: 18.12).
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 In similar secondary GLM subgroup analyses of the 
nonresponders who accepted additional therapy, there 
was a trend indicating an interaction effect (F = 2.93; p = 
0.063; observed power = 0.54). The AD nonresponders 
who accepted additional PDT had improved significant-
ly less between weeks 8 and 24 (mean T0: 20.17; mean T8: 
20.08; mean T16: 17.00; mean T24: 15.75) than the PDT 
nonresponders who accepted additional AD (mean T0: 
21.53; mean T8: 22.35; mean T16: 15.71; mean T24: 10.94).
 Discussion 
 Stepped care strategies seem clinically logical, but 
about 40% of the patients declined the offer of additional 
therapy in this study, despite the limited effect of 
monotreatment. The acceptance rate was similar in both 
conditions. Given the widespread support for and imple-
mentation of stepped care and sequential treatment strat-
egies  [13–15] , this was a rather unexpected finding. In the 
STAR * D trial, psychotherapy (cognitive therapy) as a se-
quential step also proved difficult to implement after un-
successful AD treatment  [27, 60] . However, some clear 
obstacles reported in the STAR * D trial, such as travelling 
to a different department and no payment by insurance 
companies, were absent from our sample.
 As in STAR * D, the decision to proceed with combined 
therapy in our study was based on the independent as-
sessment of HAM-D scores. However, the HAM-D does 
not differentiate between core depression symptoms – 
such as mood, anhedonia or suicidal thoughts – and ac-
cessory symptoms like lack of appetite or sleeping prob-
lems  [61–64] . Nor does it measure patients’ own evalua-
tions of the relative importance of symptoms, which may 
be a more decisive factor in the decision to accept a new 
therapy option than symptom change only.
 A total of 38% of all patients included at the outset of 
the study dropped out, mainly in the first 8 weeks. Phar-
macotherapy in depression has often been associated 
with high drop-out rates varying from 30 to 68%  [65, 66] , 
especially during the first month of treatment.
 Reported psychotherapy drop-out rates in depression 
vary from 10 to 50%  [67–70] . Settings similar to ours also 
found drop-out rates of around 40%  [9, 71] . Consequent-
ly, we do not assume that drop-out is caused by the psy-
chodynamic feature of the psychotherapy.
 A study by Warden et al.  [72] indicated that the initial 
intent of the patient with respect to continuing treatment 
is more relevant for drop-out than perceived side effects 
or a lack of efficacy during treatment. Discussing intent 
with patients at risk of drop-out before the start of thera-
py could therefore enhance adherence, alongside tele-
phone support  [66] and motivational interviewing  [73] .
 The main issue addressed by this study was the effi-
cacy of sequential strategies. Overall, the group receiving 
PDT from the outset is better off at the end of the acute 
phase of treatment. The AD strategy produced better re-
sults in the first 8 weeks (significantly lower HAM-D 
scores and more responders). However, from week 16 on-
wards, the pattern of results was reversed and, at week 24, 
Table 3.  Influence of time, intervention, addition, interaction intervention and addition on symptoms during treatment
Independent variables Dependent variables
HAM-D SCL-D CGI-S CGI-I E uroQOL
F p F p F p F p F p 
Per protocol sample
Time 20.29 0.000 23.55 0.000 39.65 0.000 13.78 0.000 3.90 0.014
Intervention AD or PDT 5.61 0.002 4.02 0.016 7.39 0.000 4.00 0.020 3.25 0.030
Addition 10.16 0.000 3.72 0.021 2.10 0.115 6.11 0.003 1.48 0.225
Intervention * addition 0.86 0.449 0.80 0.464 5.36 0.003 3.37 0.037 0.89 0.434
Observed cases sample
Time 19.89 0.000 19.74 0.000 11.23 0.000 2.47 0.096 4.81 0.008
Intervention AD or PDT 5.46 0.003 2.12 0.111 10.48 0.000 3.90 0.028 4.14 0.015
Addition 10.50 0.000 1.83 0.156 1.84 0.157 0.12 0.874 1.05 0.367
Intervention * addition 0.05 0.970 0.05 0.976 2.02 0.130 0.46 0.621 1.20 0.312
Italics = p < 0.1; bold = p < 0.05.
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the PDT group overtook the original AD group in most 
of the assessments, including quality of life scores.
 A partial explanation of the fact that the PDT sequen-
tial strategy produces better results emerges from the 
findings from the secondary analyses: the PDT patients 
who refused pharmacotherapy also remitted without 
ADs and they were better off in relative terms than the 
AD patients who refused additional psychotherapy. An-
other – additional – explanation is that pharmacotherapy 
responders lost their gain of the first 8 weeks, as opposed 
to the PDT responders who enhanced their gain (a find-
ing that emerged from the secondary analyses). Second-
ary analyses indicated that, with the CGI-I, clinicians 
tended to overestimate the actual result of pharmacother-
apy compared to patient reports. It may be advisable to 
use more specific instruments than the CGI, such as a 
short form of the HAM-D  [74] , which can be easily ad-
ministered during pharmacotherapy consultations.
 Additional psychotherapy or pharmacotherapy after 
unsuccessful monotreatment produced significantly bet-
ter results than no additional therapy. This result is com-
parable with those of Frank et al.  [16] and the STAR * D 
study  [27] . Nevertheless, because of the quasi-experimen-
tal design from week 8 onwards in this study, we do not 
know the precise reasons for the better results of the ad-
ditional therapy approach. It is possible that the prefer-
ence for addition affected factors such as hope and/or pos-
itive expectations, with a positive impact on outcome  [75] .
 There are several factors that may have affected the va-
lidity of this study and that should be addressed. The 
study population was restricted to outpatients with mild 
to moderate depressive episodes. We did not take into ac-
count the influence of personality factors or attitude to-
wards treatment options and these may be associated with 
both the acceptability and efficacy of treatment strategies 
 [76] . Furthermore, we did not take into account subtypes 
of depression  [77–79] and the decision to change therapy 
was based solely on insufficient improvement based on 
the HAM-D. However, treatment resistance may also be 
related to an inadequate approach to different subtypes of 
depression. As Bech  [80] pointed out, primary depression 
and secondary depression associated with anxiety and 
pursuant to childhood trauma or in response to separa-
tion stress may require specific treatment options.
 Finally, patients were only offered two options for ad-
ditional therapy (PDT or AD). They did not have the op-
tion of other AD treatments or different forms of psycho-
therapy, combined therapy from the outset, psychosocial 
support or long-term psychotherapy, or augmentation of 
dose  [81] .
 On the other hand, there were also enough strengths. 
At week 8, patients were not randomized at that point but 
offered a choice. Despite the complexity of this quasi-ex-
perimental design, we see it as a strength because it in-
volves a choice that approximates the real world and en-
hances the external validity of the study. The fact that the 
data were from multiple sources (independent observers, 
patients and therapists) is also a strength, as was our im-
plementation of the sequential strategy.
 This study shows that patients receiving psychothera-
py from the outset were, compared to those receiving 
pharmacotherapy, better off by week 24, when treatment 
ended. In both groups, proceeding to combined therapy 
after initial nonresponse appeared to be a beneficial strat-
egy after early nonresponse to monotreatment.
 There was a trend in which the patients who initially 
responded to pharmacotherapy failed to improve any fur-
ther and patients who did respond and who receive psycho-
therapy continued to improve throughout the treatment.
 Finally, in order to investigate the usefulness of sequen-
tial and stepped care strategies, complex and, from a sci-
entific point of view, suboptimal designs have to be used.
 Our study indicates that such studies are possible and 
could generate new data about the effectiveness of se-
quential strategies that are frequently used in day-to-day 
clinical practice.
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